RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas

REFERENCES

• Casali PG, Blay JY. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v198–203.
   PubMed Web of Science ®Google Scholar
• Schoenfeld DA, Rosenbaum C, Horton J, Wolter JM, Falkson G, DeConti RC. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 1982;50:2757–2762.
   PubMed Web of Science ®Google Scholar
• Somaiah N, von Mehren M. New drugs and combinations for the treatment of soft-tissue sarcoma: a review. Cancer Manag Res 2012;4:397–411.
   PubMedGoogle Scholar
• Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, Blay JY, Frisch J, Van Glabbeke M, Hermans C, Van Oosterom A, Tursz T, Verweij J. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18:2676–2684.
   PubMed Web of Science ®Google Scholar
• David-Cordonnier MH, Gajate C, Olmea O, Laine W, de la Iglesia-Vicente J, Perez C, Cuevas C, Otero G, Manzanares I, Bailly C, Mollinedo F. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol 2005;12:1201–1210.
   PubMed Web of Science ®Google Scholar
• Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961–966.
   PubMed Web of Science ®Google Scholar
• Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002;62:3377–3381.
   PubMed Web of Science ®Google Scholar
• Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66:8155–8162.
   PubMed Web of Science ®Google Scholar
• Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res 2001;7:185–191.
   PubMed Web of Science ®Google Scholar
• Martinez-Serra J, Maffiotte E, Martin J, Bex T, Navarro-Palou M, Ros T, Plazas JM, Vogler O, Gutierrez A, Amat JC, Ramos R, Saus C, Gines J, Alemany R, Diaz M, Besalduch J. Yondelis(R) (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action. Eur J Pharmacol 2011;658:57–64.
   PubMed Web of Science ®Google Scholar
• Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma. Cancer 2013;119:1013–1022.
   PubMed Web of Science ®Google Scholar
• Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, O'Connor R, Maki R, Viale A, Sander C, Schwartz GK, Antonescu CR. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007;67:6626–6636.
   PubMed Web of Science ®Google Scholar
• Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, Tardell C, Garrido R, Lee E, Kolinsky K, To KH, Linn M, Podlaski F, Wovkulich P, Vu B, Vassilev LT. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 2013;73:2587–2597.
   PubMed Web of Science ®Google Scholar
• Muller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 2007;121:199–205.
   PubMed Web of Science ®Google Scholar
• Moneo V, Serelde BG, Fominaya J, Leal JF, Blanco-Aparicio C, Romero L, Sanchez-Beato M, Cigudosa JC, Tercero JC, Piris MA, Jimeno J, Carnero A. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem 2007;100:339–348.
   PubMed Web of Science ®Google Scholar
• Stratford EW, Castro R, Daffinrud J, Skarn M, Lauvrak S, Munthe E, Myklebost O. Characterization of liposarcoma cell lines for preclinical and biological studies. Sarcoma 2012;2012:148614.
   PubMedGoogle Scholar
• Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, Terrier P, Ranchere-Vince D, Collin F, Myklebost O, Turc-Carel C. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 1999;24:30–41.
   PubMed Web of Science ®Google Scholar
• Sirvent N, Forus A, Lescaut W, Burel F, Benzaken S, Chazal M, Bourgeon A, Vermeesch JR, Myklebost O, Turc-Carel C, Ayraud N, Coindre JM, Pedeutour F. Characterization of centromere alterations in liposarcomas. Genes Chromosomes Cancer 2000;29:117–129.
   PubMed Web of Science ®Google Scholar
• Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979;5:85–91.
   PubMed Web of Science ®Google Scholar
• Villar VH, Vogler O, Martinez-Serra J, Ramos R, Calabuig-Farinas S, Gutierrez A, Barcelo F, Martin-Broto J, Alemany R. Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas. PLoS One 2012;7:e37735.
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844–848.
   PubMed Web of Science ®Google Scholar
• Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006;103:1888–1893.
   PubMed Web of Science ®Google Scholar
• Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805–816.
   PubMed Web of Science ®Google Scholar
• Uboldi S, Calura E, Beltrame L, Fuso Nerini I, Marchini S, Cavalieri D, Erba E, Chiorino G, Ostano P, D'Angelo D, D'Incalci M, Romualdi C. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma. PLoS One 2012;7:e35423.
   PubMed Web of Science ®Google Scholar
• Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol 2014;11:187–202.
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Hisamatsu T, Kawase C, Hayashi M, Sawada K, Mimura K, Takahashi K, Takahashi T, Kurachi H, Kimura T. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary. Clin Cancer Res 2011;17:4462–4473.
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010;70:2235–2244.
   PubMed Web of Science ®Google Scholar
• Garcia MJ, Saucedo-Cuevas LP, Munoz-Repeto I, Fernandez V, Robles MJ, Domingo S, Palacios J, Aracil M, Nieto A, Tercero JC, Benitez J. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response. Mol Cancer Ther 2013;12:530–541.
   PubMed Web of Science ®Google Scholar
• Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D'Incalci M. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97–105.
   PubMed Web of Science ®Google Scholar
• Somaiah N, von Mehren M. New drugs and combinations for the treatment of soft-tissue sarcoma: a review. Cancer Manag Res 4:397–411.
   PubMedGoogle Scholar
• Ohnstad HO, Paulsen EB, Noordhuis P, Berg M, Lothe RA, Vassilev LT, Myklebost O. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines. BMC Cancer 2011;11:211–211.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, Geho D, Middleton SA, Vassilev LT, Nichols GL, Bui BN. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012;13:1133–1140.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28:3107–3114.
   PubMed Web of Science ®Google Scholar